The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | CONPET study: KRd consolidation abrogates poor prognosis of FDG PET/CT positivity after autoSCT
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, presents the results of the Phase II CONPET study (NCT03314636), which investigated the impact of consolidation therapy with carfilzomib, lenalidomide and dexamethasone (KRd) on patients with multiple myeloma (MM) with positive FDG PET/CT scans after autologous stem cell transplantation (autoSCT). Dr Schjesvold highlights that the study found that one-third of patients with PET-positive status became PET-negative after receiving intensive consolidation therapy, and their progression-free survival (PFS) and overall survival (OS) outcomes are similar to those patients who were PET-negative at enrollment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The CONPET was published last year. It was a study of 150 patients after transplant that were in at least VGPR. The intention was that we know that those at that stage after transplant, if they still have a positive PET, their survival is worse, that’s from a French study some years ago published by Philippe Moreau. So it used that population and gave them more treatment...
The CONPET was published last year. It was a study of 150 patients after transplant that were in at least VGPR. The intention was that we know that those at that stage after transplant, if they still have a positive PET, their survival is worse, that’s from a French study some years ago published by Philippe Moreau. So it used that population and gave them more treatment. So of the 150 people in VGPR that we screened after transplant, 100 were PET-negative, but 50 were PET-positive. Those 50 were treated with four consolidation cycles of carfilzomib and lenalidomide and dexamethasone. And the endpoint was how many then became PET-negative after this and also the MRD bone marrow sampling.
So what we saw was that, this was published last year in Leukemia, that one third of the patients did become PET-negative, and they were more likely to do that if they also were MRD-negative at inclusion. What we are presenting now is follow-up data. And what we’re looking at now is what happens with PFS and OS in the two cohorts because then you have… it’s not a randomized trial but you have 50 patients that are PET-positive with a bad prognosis, 100 PET-negative with a good prognosis, and we gave the PET-positive more treatment, so now we have compared those two groups in terms of PFS and OS. OS is still early, but the PFS looks extremely similar. So it’s not a randomized trial, but it’s an indication that by giving more intensive treatment after transplant to patients with PET positivity, you could make their prognosis more similar to the PET negatives. So that’s sort of the major result of the thing I’m presenting here this year.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
